Oncotarget

Research Papers:

An oncogenic KRAS transcription program activates the RHOGEF ARHGEF2 to mediate transformed phenotypes in pancreatic cancer

Oliver A. Kent _, María-José Sandí, Helen E. Burston, Kevin R. Brown and Robert Rottapel

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:4484-4500. https://doi.org/10.18632/oncotarget.13152

Metrics: PDF 1012 views  |   HTML 1879 views  |   ?  


Abstract

Oliver A. Kent1, María-José Sandí1, Helen E. Burston1, Kevin R. Brown2, Robert Rottapel1,3,4,5,6

1Princess Margaret Cancer Centre, University Health Network, Toronto Medical Discovery Tower, University of Toronto, Toronto, Canada

2Donnelly Centre and Banting and Best Department of Medical Research, University of Toronto, Toronto, Canada

3Department of Medicine, St. Michael’s Hospital, Toronto, Canada

4Department of Medical Biophysics, St. Michael’s Hospital, Toronto, Canada

5Department of Immunology, St. Michael’s Hospital, Toronto, Canada

6Division of Rheumatology, St. Michael’s Hospital, Toronto, Canada

Correspondence to:

Oliver A. Kent, email: kent.uhn@gmail.com

Robert Rottapel, email: rottapel@gmail.com

Keywords: KRAS, ARHGEF2, GEFH1, transcription, pancreatic

Received: July 29, 2016    Accepted: October 13, 2016    Published: November 7, 2016

ABSTRACT

Activating mutations of KRAS are nearly ubiquitous in pancreatic adenocarcinomas occurring in greater than 90% of cases. Cellular transformation by oncogenic RAS requires the RHO guanine exchange factor ARHGEF2 (also known as GEF-H1) for tumor growth and survival. Here, we find oncogenic KRAS activates ARHGEF2 through a minimal RAS responsive promoter. We have determined the endogenous ARHGEF2 promoter is positively regulated by the transcription factors ELK1, ETS1, SP1 and SP3 and negatively regulated by the RAS responsive element binding protein (RREB1). We find that the panel of ARHGEF2-regulating transcription factors modulates RAS transformed phenotypes including cellular viability, anchorage-independent growth and invasion-migration of pancreatic cancer cells. RREB1 knockdown activates the amplitude and duration of RHOA via increased ARHGEF2 expression. By relieving the negative regulation of RREB1 on the ARHGEF2 promoter, we determined that ETS1 and SP3 are essential for the normal expression of ARHGEF2 and contribute to the migratory behavior of pancreatic cancer cells. Furthermore, enforced expression of ARHGEF2 rescues loss of SP3 driven invasion-migration and anchorage-independent growth defective phenotypes through restored activation of RHOA. Collectively, our results identify a transcription factor program required for RAS transformation and provide mechanistic insight into the highly metastatic behavior of pancreatic cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 13152